CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab (CANARI)

There are limited prospective data regarding the potential benefit and risks associated with switching between anti-VEGF therapies in patients with nAMD who have initially achieved a favorable response to the first anti-VEGF therapy used but subsequently have evidence of increasing disease activity despite continuation of therapy. This study will fill this knowledge gap by prospectively evaluating the effectiveness and safety of switching from aflibercept to ranibizumab in nAMD patients that have non - sustained response to initial treatment with aflibercept.

Study Overview

• Status: Withdrawn
• Conditions: Wet Age-related Macular Degeneration (Wet AMD)
• Intervention / Treatment: Drug: Ranibizumab

• Study Type: Interventional
• Phase: Phase 4

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 50 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• BCVA ≥23 ETDRS letters in study eye at both the Screening and Baseline visits.
• Evidence, at Screening, of active, angiographically confirmed Choroidal Neovascularization (CNV) secondary to AMD, directly or indirectly affecting the center of the fovea in study eye.
• No prior anti-VEGF treatment other than aflibercept.

Exclusion Criteria:

• History of cerebrovascular accident, transient ischemic attack or myocardial infarction within 3 months of the Screening visit.
• Any type of systemic disease or its treatment, including any medical condition (controlled or uncontrolled) that could be expected to progress, recur, or change to such an extent that it may bias the assessment of the clinical status of the patient to a significant degree or put the patient at special risk.

Exclusion criteria for ocular medical history and conditions for either eye:

• Any active periocular or ocular infection, or active intraocular inflammation at the time of Screening or Baseline (as per contraindications in the Lucentis® Product Monograph).
• Uncontrolled glaucoma (intraocular pressure [IOP] ≥30 mm Hg on medication or according to Investigator's judgment) at the time of Screening or Baseline
• Evidence of bilateral active CNV during the Screening Period or at Baseline requiring bilateral anti-VEGF injections.
• Prior intravitreal injection of ranibizumab or bevacizumab into the study eye and/or prior intravitreal injection of bevacizumab into the fellow eye.

Study eye exclusion criteria:

• At Baseline, intraocular surgery was performed within the previous 28 days or intraocular surgery is planned at any time during the 6 month study period
• Cataract (if causing significant visual impairment), aphakia, severe vitreous hemorrhage, rhegmatogenous retinal detachment, proliferative retinopathy or choroidal neovascularization of any other cause than wet AMD (e.g. ocular histoplasmosis, pathologic myopia (≥-8 dioptres)) at the time of Screening and Baseline.
• Irreversible structural damage involving the center of the fovea (e.g. advanced fibrosis or geographic atrophy) which in the opinion of the Investigator is sufficient to irreversibly impair visual acuity.
• Polypoidal choroidal vasculopathy (PCV), RPE tear, central serous retinopathy (CSR), or significant vitreomacular traction identified during Screening period or within 4 months of Baseline visit. Note that small vitreomacular adhesions that do not result in deformity of the retina are permitted.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Ranibizumab at 0.5 mg; Single arm, intravitreal injection	Drug: Ranibizumab; 0.5 mg, intravitreal injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean change in Central Subfield Retinal Thickness (CSRT)	Change (in absolute and percentage terms) in central subfield retinal thickness (CSRT) measured by spectral domain/ high definition optical coherence tomography (SD/HD-OCT).	at Day 90 (Month 3) and Day 180 (Month 6)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean change in Central Subfield Retinal Thickness (CSRT)	Change (in absolute and percentage terms) in central subfield retinal thickness (CSRT) measured by spectral domain/ high definition optical coherence tomography (SD/HD-OCT).	Monthly, from baseline to Month 6
Mean change in Subfoveal Retinal Thickness (SRT)	Change (in absolute and percentage terms) in subfoveal retinal thickness (SRT) measured by spectral domain/ high definition optical coherence tomography (SD/HD-OCT).	Monthly, from baseline to Month 6
Change in Central Subfield Retinal Volume (CSRV)	Change (in absolute and percentage terms) in subfoveal retinal thickness (SRT) measured by spectral domain/ high definition optical coherence tomography (SD/HD-OCT).	Monthly, from baseline to Month 6
Mean change in Subretinal Fluid (SF)	Measured through Optical Coherence Tomography (OCT).	Monthly, from baseline to Month 6
Mean change in Intra-Retinal Cystoid changes (IRCs) volume	Measured through Optical Coherence Tomography (OCT).	Monthly, from baseline to Month 6
Mean change in Pigment Epithelial Detachments (PEDs)	Measured through Optical Coherence Tomography (OCT).	Monthly, from baseline to Month 6
Mean change of Best-Corrected Visual Acuity (BCVA)	Best-corrected visual acuity (BCVA) will be assessed in a sitting position using subjective refraction and ETDRS-like visual acuity testing charts.	Monthly, from baseline to Month 6
Rate of change in Subfoveal Retinal Thickness (SRT)	Rates will be assessed with the proportion of patients with changes.	Monthly, from baseline to Month 6
Rate of change in Central Subfield Retinal Thickness (CSRT)	Rates will be assessed with the proportion of patients with changes.	Monthly, from baseline to Month 6
Rate of change in Intra-Retinal Cystoid (IRCs)	Rates will be assessed with the proportion of patients with changes.	Monthly, from baseline to Month 6
Rate of change in Pigment Epithelial Detachments (PEDs)	Rates will be assessed with the proportion of patients with changes.	Monthly, from baseline to Month 6
Rate of Dry Retina	Rates will be assessed with the proportion of patients with changes.	Monthly, from baseline to Month 6

Collaborators and Investigators

• Sponsor: Novartis Pharmaceuticals

Study record dates

Study Major Dates

• Study Start (Anticipated): March 1, 2016
• Primary Completion (Anticipated): December 1, 2017
• Study Completion (Anticipated): December 1, 2017

Study Registration Dates

• First Submitted: December 16, 2015
• First Submitted That Met QC Criteria: December 16, 2015
• First Posted (Estimate): December 18, 2015

Study Record Updates

• Last Update Posted (Actual): February 15, 2017
• Last Update Submitted That Met QC Criteria: February 14, 2017
• Last Verified: February 1, 2017

More Information

Terms related to this study

• Keywords: wet AMD, ranibizumab, aflibercept, neovascularization
• Additional Relevant MeSH Terms: Eye Diseases; Retinal Degeneration; Retinal Diseases; Macular Degeneration; Physiological Effects of Drugs; Antineoplastic Agents; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Ranibizumab
• Other Study ID Numbers: CRFB002ACA09